Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib + Pembrolizumab in Recurrent/Progressive IDH-1 Mutant Glioma
NCT05484622Phase 1Active, not recruiting
- Sponsor
- Servier
- Start
- Jan 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vorasidenib in glioma (4 arms), sponsored by Servier. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 19 months and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05484622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484622.